Effet de la déleucocytation des concentrés érythrocytaires sur les réactions transfusionnelles

Mukagatare, I.; Monfort, Mélanie; Marchin, Jérôme de; Gérard, Christiane

doi:10.1016/j.tracli.2009.12.001

Cited by 6 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[42][43][44] Recent research has shown a potential link between stored vs. fresh non-leuco-reduced human RBC transfusion and the risk of TRALI, 45 although not found in premature, very low-birth-weight infants. 46 Other conditions such as haemolytic transfusion reaction caused by pre-existing antibody in the recipient (ABO incompatibility); 47 Febrile non-haemolytic transfusion reaction due to pyrogenic cytokines released from donor leukocytes; 48 Alloimmunisation with subsequent haemolytic reactions due to presence of allo-antibodies against donor antigens in patients receiving multiple transfusions 4 and transfusionassociated graft vs. host disease in which the immunocompetent donor T-lymphocytes mount an immunologic reaction against the recipient's lymphoid tissue 13,39 are some of the most important immune-mediated complications (Table 2). However, the reported incidences of transfusionassociated risks in paediatrics are very uncertain with wide variations due to scarcity of data.…”

Section: Immune-mediated Risksmentioning

confidence: 99%

Transfusion in critically ill children: an ongoing dilemma

Secher

Stensballe

Afshari

2013

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

Transfusion of blood products is a cornerstone in managing many critically ill children. Major improvements in blood product safety have not diminished the need for caution in transfusion practice. In this review, we aim to discuss the interplay between benefits and potential adverse effects of transfusion in critically ill children by including 65 papers, which were evaluated based on previously agreed selection criteria. Current practice on transfusing critically ill children is mainly founded on the basis of adult studies, common practices with cut-off values, and expert opinions, rather than evidence-based medicine. Paediatric patients have explicit physiological challenges and requirements to be addressed. Critically ill children often suffer from anaemia, have substantial iatrogenic blood loss with subsequent transfusions, and are at a higher risk of complications, often due to human errors. Transfusion in children is associated with increased morbidity. A restrictive transfusion strategy is not associated with increased morbidity. Thus, transfusion in paediatrics should be considered a high-risk treatment and requires individual clinical assessment. Current level of evidence support the notion that in most stable cases, despite high severity of illness (cyanotic children and neonates excluded), a restrictive haemoglobin threshold of 70 g/l (4.3 mmol/l) is no more harmful than to transfuse at a liberal trigger, e.g. haemoglobin 95 g/l (5.9 mmol/l). Thus, balanced against potential benefits and often its necessity, a restrictive approach may be appropriate due to the associated risks of transfusion.

show abstract

Section: Immune-mediated Risksmentioning

confidence: 99%

Transfusion in critically ill children: an ongoing dilemma

Secher

Stensballe

Afshari

2013

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

show abstract

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Simancas‐Racines¹,

Martí‐Carvajal²,

Hidalgo³

et al. 2012

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Simancas‐Racines

Osorio

Martí‐Carvajal³

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundA blood transfusion is an acute intervention, implemented to solve life and health-threatening conditions on a short-term basis. However, blood transfusions have adverse events, some of them potentially related to immune modulation or to a direct transmission of infectious agents (e.g. cytomegalovirus). Leukoreduction is a process in which the white blood cells are intentionally reduced in packed red blood cells (PRBCs) in order to reduce the risk of adverse reactions. The potential benefits of leukoreduced PRBCs in all types of transfused patients for decreasing infectious and non-infectious complications remain unclear. ObjectivesTo determine the clinical effectiveness of leukoreduction of packed red blood cells for preventing adverse reactions following allogeneic blood transfusion. Search methodsWe ran the most recent search on 10th November 2015. We searched the Cochrane Injuries Group's Specialised Register, Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Library), MEDLINE (OvidSP), Embase(OvidSP), CINAHL Plus (EBSCO), LILACS (BIREME), and clinical trials registers. In addition, we checked the reference lists of all relevant trials and reviews identified in the literature searches. Selection criteriaRandomised clinical trials including patients of all ages requiring PRBC allogeneic transfusion. Any study was eligible for inclusion, regardless of the length of participant follow-up or country where the study was performed. The primary outcome was transfusion-related acute lung injury (TRALI). Secondary outcomes were death from any cause, infection from any cause, non-infectious complications and any other adverse event.1 Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion (Review)

show abstract

Effet de la déleucocytation des concentrés érythrocytaires sur les réactions transfusionnelles

Cited by 6 publications

References 10 publications

Transfusion in critically ill children: an ongoing dilemma

Transfusion in critically ill children: an ongoing dilemma

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Leukoreduction for the prevention of adverse reactions from allogeneic blood transfusion

Contact Info

Product

Resources

About